We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+15.5%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.17B
AUM Growth
+$187M
Cap. Flow
-$13.4M
Cap. Flow %
-0.62%
Top 10 Hldgs %
27.68%
Holding
163
New
13
Increased
39
Reduced
20
Closed
16

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$28M
2
IRTC icon
iRhythm Holdings
IRTC
+$17.5M
3
PBYI icon
Puma Biotechnology
PBYI
+$13.4M
4
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$10.8M
5
MOH icon
Molina Healthcare
MOH
+$10.4M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$37.9M
2
HUM icon
Humana
HUM
+$31.9M
3
HOLX
Hologic
HOLX
+$19.1M
4
MDT icon
Medtronic
MDT
+$12.7M
5
WBA
Walgreens Boots Alliance
WBA
+$6.74M

Sector Composition

Rank Sector Weight
1 Healthcare 80.49%
2 Financials 3.75%
3 Consumer Discretionary 0.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANAB icon
101
AnaptysBio
ANAB
$1.68B
$5.24M 0.24%
+150,000
New +$4.05M
NBRV
102
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$5.12M 0.24%
2,500
+400
+19% +$938K
BLUE
103
DELISTED
bluebird bio
BLUE
$4.81M 0.22%
2,702
+232
+9% +$324K
GBT
104
DELISTED
Global Blood Therapeutics, Inc.
GBT
$4.66M 0.21%
150,000
– –
MYOV
105
DELISTED
Myovant Sciences Ltd.
MYOV
$4.57M 0.21%
295,100
+145,100
+97% +$1.76M
KDNY
106
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$4.42M 0.2%
83,000
– –
EXEL icon
107
Exelixis
EXEL
$13.4B
$4.24M 0.2%
175,000
– –
MGNX icon
108
MacroGenics
MGNX
$257M
$4.16M 0.19%
225,000
– –
AGN.PRA
109
DELISTED
Allergan plc
AGN.PRA
$3.79M 0.17%
5,000
– –
CBAY
110
DELISTED
Cymabay Therapeutics
CBAY
$3.63M 0.17%
+450,000
New +$3.04M
DVAX
111
DELISTED
Dynavax Technologies
DVAX
$3.55M 0.16%
165,000
– –
MCRB icon
112
Seres Therapeutics
MCRB
$48.4M
$3.53M 0.16%
11,000
– –
ZGNX
113
DELISTED
Zogenix, Inc.
ZGNX
$3.5M 0.16%
+100,000
New +$1.36M
BMY icon
114
Bristol-Myers Squibb
BMY
$132B
$3.19M 0.15%
50,000
– –
IRWD icon
115
Ironwood Pharmaceuticals
IRWD
$714M
$3.15M 0.15%
+238,800
New +$3.29M
CGEN icon
116
Compugen
CGEN
$228M
$3.13M 0.14%
825,000
– –
DBVT
117
DBV Technologies
DBVT
$847M
$3.1M 0.14%
7,300
– –
ITCI
118
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.96M 0.14%
187,500
– –
SYRE icon
119
Spyre Therapeutics
SYRE
$9.25B
$2.58M 0.12%
20,964
– –
CORV
120
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$2.57M 0.12%
1,200,000
– –
RIGL icon
121
Rigel Pharmaceuticals
RIGL
$750M
$2.54M 0.12%
100,000
– –
ZBH icon
122
Zimmer Biomet
ZBH
$18.4B
$2.47M 0.11%
21,733
– –
CDTX
123
DELISTED
Cidara Therapeutics
CDTX
$2.43M 0.11%
15,000
– –
ATYR
124
aTyr Pharma
ATYR
$50.1M
$2.4M 0.11%
33,929
– –
BCRX icon
125
BioCryst Pharmaceuticals
BCRX
$2.4B
$2.36M 0.11%
+450,000
New +$2.3M
3 4
5
6 7

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2017 Portfolio in Review

As of Q3 2017, Rock Springs Capital Management held 163 positions worth $2.17B, up 9.5% from $1.98B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Rock Springs Capital Management's Q3 2017 filing shows 13 new, 39 increased, 20 reduced and 16 closed positions. Its largest new stake was iRhythm Holdings: 386,000 shares worth $20M. The largest sale was Allergan plc, an estimated $37.9M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 80% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Rock Springs Capital Management's largest Q3 2017 buy was iRhythm Holdings: 386,000 shares worth $20M.
  • Rock Springs Capital Management added most to UnitedHealth in Q3 2017, an estimated $28M increase.
  • Rock Springs Capital Management's biggest Q3 2017 reduction was Medtronic, cutting an estimated $12.7M.
  • Rock Springs Capital Management fully exited Allergan plc in Q3 2017, selling an estimated $37.9M.
  • Rock Springs Capital Management's ten largest holdings make up 28% of its $2.17B portfolio in Q3 2017.
  • Rock Springs Capital Management opened 13 new positions and closed 16 in Q3 2017.
  • Rock Springs Capital Management's portfolio value rose 9.5% quarter-over-quarter to $2.17B.

Based on Rock Springs Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.